All news

A director exercises warrants at $0.0004 per depositary share in Akari Therapeutics (AKTX).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Akari Therapeutics director Sandip I. Patel exercised pre-funded warrants for 10,052 ADSs at $0.0004 per share and received RSU awards for 16,413 ADSs and options for 60,000 ADSs. These RSU and option grants are subject to shareholder approval of an equity plan amendment and have specific vesting schedules.

Read original source

AKTX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.